All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What is the benefit of adding pevonedistat to azacitidine in patients with high-risk MDS or AML?
Bookmark this article
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the MDS Hub was delighted to speak to Lionel Ades, Saint-Louis Hospital, Paris, FR. We asked: what is the benefit of adding pevonedistat to azacitidine in patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)?
What is the benefit of adding pevonedistat to azacitidine in patients with high-risk MDS or AML?
In this video, Lionel Ades describes the results of the phase II study that evaluated this combination in patients who had not previously received hypomethylating agents and were ineligible for stem cell transplant. He describes the event-free survival results of the 120 patients enrolled in the study as well as the overall survival and duration of response in the three patient populations: high-risk MDS, high-risk AML or low blast AML.
Related articles
Newsletter
Subscribe to get the best content related to MDS delivered to your inbox